LEGEND BIOTECH CORP-ADR (LEGN) Stock Overview
NASDAQ:LEGN - US52490G1022 - ADR
LEGN Key Statistics, Chart & Performance
The current stock price of LEGN is 35.95 USD. In the past month the price decreased by -6.43%. In the past year, price decreased by -25.55%.
LEGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.01 | 374.26B | ||
| AMGN | AMGEN INC | 13.01 | 152.81B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.41 | 101.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.35 | 59.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.65B | ||
| ARGX | ARGENX SE - ADR | 77.89 | 44.19B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.78 | 39.97B | ||
| INSM | INSMED INC | N/A | 30.33B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.14B | ||
| NTRA | NATERA INC | N/A | 22.99B | ||
| BIIB | BIOGEN INC | 8.85 | 20.76B |
Related stock screener links
About LEGN
Company Profile
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey and currently employs 2,800 full-time employees. The company went IPO on 2020-06-04. The firm is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. The company is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Company Info
LEGEND BIOTECH CORP-ADR
2101 Cottontail Lane
Somerset NEW JERSEY 08873 US
CEO: Ying Huang
Employees: 2600
Phone: 17328505598
LEGEND BIOTECH CORP-ADR / LEGN FAQ
What is the stock price of LEGEND BIOTECH CORP-ADR today?
The current stock price of LEGN is 35.95 USD. The price increased by 5.06% in the last trading session.
What is the ticker symbol for LEGEND BIOTECH CORP-ADR stock?
The exchange symbol of LEGEND BIOTECH CORP-ADR is LEGN and it is listed on the Nasdaq exchange.
On which exchange is LEGN stock listed?
LEGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LEGEND BIOTECH CORP-ADR stock?
28 analysts have analysed LEGN and the average price target is 76.34 USD. This implies a price increase of 112.36% is expected in the next year compared to the current price of 35.95. Check the LEGEND BIOTECH CORP-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LEGEND BIOTECH CORP-ADR worth?
LEGEND BIOTECH CORP-ADR (LEGN) has a market capitalization of 6.60B USD. This makes LEGN a Mid Cap stock.
How many employees does LEGEND BIOTECH CORP-ADR have?
LEGEND BIOTECH CORP-ADR (LEGN) currently has 2600 employees.
What are the support and resistance levels for LEGEND BIOTECH CORP-ADR (LEGN) stock?
LEGEND BIOTECH CORP-ADR (LEGN) has a support level at 35.04 and a resistance level at 35.96. Check the full technical report for a detailed analysis of LEGN support and resistance levels.
Is LEGEND BIOTECH CORP-ADR (LEGN) expected to grow?
The Revenue of LEGEND BIOTECH CORP-ADR (LEGN) is expected to grow by 69.61% in the next year. Check the estimates tab for more information on the LEGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LEGEND BIOTECH CORP-ADR (LEGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LEGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LEGN, evaluating the profitability, health, valuation and growth aspects
- LEGEND BIOTECH CORP-ADR (LEGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LEGEND BIOTECH CORP-ADR (LEGN) Sales and EPS estimates to see what analysts future expectations are.
- LEGEND BIOTECH CORP-ADR (LEGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LEGEND BIOTECH CORP-ADR (LEGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- LEGEND BIOTECH CORP-ADR (LEGN) Stock Chart to make your own analysis
- LEGEND BIOTECH CORP-ADR (LEGN) Latest news and press-releases to stay up to date.
Does LEGEND BIOTECH CORP-ADR (LEGN) stock pay dividends?
LEGN does not pay a dividend.
When does LEGEND BIOTECH CORP-ADR (LEGN) report earnings?
LEGEND BIOTECH CORP-ADR (LEGN) will report earnings on 2025-11-10, before the market open.
What is the Price/Earnings (PE) ratio of LEGEND BIOTECH CORP-ADR (LEGN)?
LEGEND BIOTECH CORP-ADR (LEGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.75).
What is the Short Interest ratio of LEGEND BIOTECH CORP-ADR (LEGN) stock?
The outstanding short interest for LEGEND BIOTECH CORP-ADR (LEGN) is 8.38% of its float. Check the ownership tab for more information on the LEGN short interest.
LEGN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to LEGN. When comparing the yearly performance of all stocks, LEGN is a bad performer in the overall market: 84.64% of all stocks are doing better.
LEGN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LEGN. The financial health of LEGN is average, but there are quite some concerns on its profitability.
LEGN Financial Highlights
Over the last trailing twelve months LEGN reported a non-GAAP Earnings per Share(EPS) of -1.75. The EPS decreased by -12.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.25% | ||
| ROE | -31.42% | ||
| Debt/Equity | 0.37 |
LEGN Forecast & Estimates
28 analysts have analysed LEGN and the average price target is 76.34 USD. This implies a price increase of 112.36% is expected in the next year compared to the current price of 35.95.
For the next year, analysts expect an EPS growth of 7.73% and a revenue growth 69.61% for LEGN